The FDA has granted a regular approval to venetoclax (Venclexta) for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma , with or without 17p deletion, following at least 1 prior therapy.
Original Article: FDA Grants Venetoclax Full Approval for CLL, Regardless of 17p Deletion